Please login to the form below
Glycotope appoints Dr Alfredo Zurlo as chief medical officer
He joins the German clinical-stage immuno-oncology company from Mologen
German clinical-stage
immuno-oncology company Glycotope has appointed Dr Alfredo Zurlo as chief
medical officer.
He joins the firm from Mologen AG, where he was its chief medical officer and a member of the Berlin-based biotech's executive board.
Prior that Dr Zurlo held various positions at F Hoffmann La Roche and Roche SA, including senior international medical leader director oncology and medical director oncology.
Previous to his time at Roche he was a medical advisor for the European Organisation for the Research and Treatment of Cancer (EORTC).
Glycotope's chief executive officer Paul Higham said: “We are delighted that Alfredo has decided to join Glycotope. He has an exceptionally strong background in oncology both in a clinical setting and within companies developing and marketing treatments for cancer.
“His experience in designing and managing clinical trials will be invaluable as we continue to advance our mature and growing pipeline of proprietary cancer therapies including our oncology lead PankoMab-GEX which is currently in phase IIb in ovarian cancer.“
COVID-19 Updates and Daily News
Featured jobs
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
-
Account Management
-
Competitive Salary Offered
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Senior Content Editor - Biotechnology
-
Salary TBC
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Virtual congresses: video thrilled the cardio tsar
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- CureVac expands COVID-19 vaccine trial protocol to include variant specification
- US pauses rollout of J&J’s COVID-19 vaccine amid reports of rare blood clots
- Follow the user – democratising medical conference design
- How a design mindset can lead to better medical outcomes
- How does the government plan to reshape the NHS?
- Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
- Oxford study finds standard asthma medication improves recovery time in COVID-19 patients
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- How a design mindset can lead to better medical outcomes
- By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
- How does the government plan to reshape the NHS?
- Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
- Want to give perfect client service? Tough luck, you’re human
- In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
Quick links
Infographics
